Get the Stockscreener App
20.84
4.12%
0.825
Newamsterdam Pharma Company Nv stock is traded at $20.84, with a volume of 520.31K.
It is up +4.12% in the last 24 hours and down -1.54% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
See More
Previous Close:
$20.01
Open:
$20.3
24h Volume:
520.31K
Relative Volume:
0.37
Market Cap:
$2.49B
Revenue:
$22.57M
Net Income/Loss:
$-212.73M
P/E Ratio:
-11.55
EPS:
-1.8045
Net Cash Flow:
$-142.19M
1W Performance:
-2.00%
1M Performance:
-1.54%
6M Performance:
-38.74%
1Y Performance:
-48.49%
1-Day Range:
$20.21
$21.12
1-Week Range:
$19.58
$21.97
52-Week Range:
$19.58
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
20.84 | 2.49B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
508.71 | 128.94B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.63 | 95.27B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.98 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
855.28 | 53.79B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.53 | 42.37B | 5.76B | 514.49M | 1.10B | 4.4813 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-26 | Initiated | BMO Capital Markets | Outperform |
| Mar-18-26 | Initiated | Truist | Buy |
| Oct-20-25 | Resumed | H.C. Wainwright | Buy |
| Aug-25-25 | Initiated | Wells Fargo | Overweight |
| Jul-17-25 | Initiated | Goldman | Neutral |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jun-10-25 | Initiated | Stifel | Buy |
| Jun-04-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
After exercising options, Futurum sold 50,246 NewAmsterdam Pharma (NAMS) shares at an average $25.03. - stocktitan.net
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Seven new hires receive stock options to buy NewAmsterdam shares at $24.16 each. - stocktitan.net
Five Frazier funds detail their NewAmsterdam (NASDAQ: NAMS) positions - Stock Titan
NewAmsterdam Pharma (NasdaqGM:NAMS) Stock Forecast & Analyst Predictions - Simply Wall Street
NewAmsterdam Pharma (NAMS) CEO adds to stake with fresh share purchase - Stock Titan
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test - Investing.com
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test By Investing.com - Investing.com UK
Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma at Wells Fargo conference: obicetrapib push By Investing.com - Investing.com UK
NewAmsterdam Pharma (NAMS) director sells shares to cover tax bill - Stock Titan
Newamsterdam Pharma stock hits 52-week low at 23.02 USD - investing.com
Newamsterdam Pharma stock hits 52-week low at 23.02 USD - Investing.com India
Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com UK
NewAmsterdam Pharma: Potential Coupled With Uncertainty (NASDAQ:NAMS) - Seeking Alpha
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com South Africa
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com India
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com UK
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com
Price to earnings forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NewAmsterdam Pharma Company N.V. - Reuters
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma VP Robert Gunning Granted 3,200 RSUs and 14,000 Stock Options - kalkinemedia.com
NewAmsterdam Pharma (NAMS) awards 14,000 options and 3,200 RSUs to controller - Stock Titan
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NAMS Q2 2026 Earnings: Quarterly Net Loss Widens Slightly on R&D InvestmentPre-Earnings Setup - vinanet.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
New hires receive options to buy NewAmsterdam shares at $24.92. Some awards vest over four years. - Stock Titan
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - The Manila Times
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - GlobeNewswire
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Barchart.com
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - kalkine.ca
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - Kalkine
NewAmsterdam Pharma (NASDAQ: NAMS) affiliate plans Nasdaq share sale over 90 days - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) affiliate readies Nasdaq share sale - Stock Titan
NewAmsterdam (NAMSW) Shares: Moves 3.19% Higher to $16.51; Level Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingFactor Momentum - vinanet.vn
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayMargin Expansion Trends - dars.gov.et
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Miss Alert - dars.gov.et
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayDownward Estimate Revision - dars.gov.et
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Acceleration Picks - vinanet.vn
NewAmsterdam (NAMSW) Shares: Shows Minimal Net Change at $16.00 in Latest Trading; Trading Range: Support at $15.20 and Resistance at $16.80 Frame the Range in the Latest SessionSingle Stock ETF - vinanet.vn
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Newamsterdam Pharma Company Nv Stock (NAMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Davidson Michael H. | Chief Executive Officer |
Sep 14 '26 |
Buy |
22.65 |
10,000 |
226,500 |
792,923 |
| Smither John W | Director |
Sep 04 '26 |
Sale |
25.32 |
1,600 |
40,512 |
8,760 |
| Kastelein Johannes Jacob Piete | Chief Scientific Officer |
Aug 24 '26 |
Sale |
26.91 |
125,000 |
3,363,750 |
69,302 |
| Kastelein Johannes Jacob Piete | Affiliate |
Aug 24 '26 |
Proposed Sale |
27.87 |
125,000 |
3,483,750 |
0 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jul 20 '26 |
Option Exercise |
11.34 |
105,000 |
1,191,100 |
129,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jul 20 '26 |
Sale |
30.34 |
105,000 |
3,185,656 |
24,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jun 22 '26 |
Option Exercise |
11.28 |
40,000 |
451,000 |
64,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jun 22 '26 |
Sale |
30.20 |
40,000 |
1,208,159 |
24,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
May 26 '26 |
Sale |
35.69 |
65,000 |
2,319,850 |
24,353 |
| Louise Kooij | Officer |
May 26 '26 |
Proposed Sale |
35.44 |
210,000 |
7,442,400 |
0 |
4.04%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):